KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Non Operating Income (2016 - 2025)

Historic Non Operating Income for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $912000.0.

  • TherapeuticsMD's Non Operating Income rose 6084.66% to $912000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 3480.87%. This contributed to the annual value of $2.4 million for FY2024, which is 20947.5% up from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's Non Operating Income is $912000.0, which was up 6084.66% from $1.2 million recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's Non Operating Income peaked at $25.3 million during Q4 2021, and registered a low of -$22.8 million during Q1 2022.
  • In the last 5 years, TherapeuticsMD's Non Operating Income had a median value of $58000.0 in 2023 and averaged -$919947.4.
  • Over the last 5 years, TherapeuticsMD's Non Operating Income had its largest YoY gain of 289827.59% in 2024, and its largest YoY loss of 238518.52% in 2024.
  • Over the past 5 years, TherapeuticsMD's Non Operating Income (Quarter) stood at $25.3 million in 2021, then crashed by 99.96% to $11000.0 in 2022, then surged by 145.45% to $27000.0 in 2023, then plummeted by 2385.19% to -$617000.0 in 2024, then skyrocketed by 247.81% to $912000.0 in 2025.
  • Its Non Operating Income stands at $912000.0 for Q3 2025, versus $1.2 million for Q2 2025 and $203000.0 for Q1 2025.